Eli Lilly Leverages AI to Transform Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 15 2026
0mins
Should l Buy LLY?
Source: Fool
- AI Platform Launch: Eli Lilly launched the TuneLab platform in September last year, allowing other drugmakers digital access to proprietary data on drug molecule performance, which saves significant time and money, enabling companies to focus on their best research projects.
- Major Investment Partnership: Eli Lilly partnered with Nvidia, committing $1 billion to build a supercomputer aimed at deepening disease understanding and advancing drug development, marking a significant step in the company's AI drug development efforts.
- Huge Market Potential: According to Straits Research, the AI-powered drug discovery industry is expected to grow at an annual rate of 30% through 2034, reaching over $20 billion, providing Eli Lilly with substantial future revenue opportunities.
- Increased Collaboration Opportunities: By owning a powerful drug development platform, Eli Lilly can not only optimize its own research but also establish partnerships with smaller pharmaceutical companies, helping them bring new drugs to market and enhancing its competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 934.600
Low
950.00
Averages
1192
High
1500
Current: 934.600
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
Eli Lilly's Foundayo Struggles Against Wegovy in Weight Loss Market
- Market Acceptance Analysis: Eli Lilly's oral GLP-1 drug Foundayo recorded 5,612 prescriptions in its third week, indicating low market acceptance, especially compared to Novo Nordisk's oral Wegovy, which had over 134,000 prescriptions in the same period, highlighting Wegovy's first-mover advantage.
- Patient Treatment Status: As of April 30, Eli Lilly executives reported that over 20,000 patients have been treated with Foundayo; however, this figure appears weak compared to Wegovy's market performance, potentially leading to negative investor sentiment.
- Future Expectations: RBC Capital Markets analyst Trung Huynh expects Foundayo to exceed 90,000 prescriptions by week 12 to stay on track for its annual sales expectation of about $1.4 billion, and achieving this target will directly impact Eli Lilly's market performance and investor confidence.
- Financial Outlook: Eli Lilly projects revenues of $82 billion to $85 billion by 2026, with non-GAAP EPS expected between $35.50 and $37, positioning Foundayo's launch as a crucial component for achieving these targets, despite its current underwhelming market performance.
See More
Apple's Strong Earnings Propel Market to New Highs
- Market Highs: The S&P 500 reached a new intra-day high on Friday, driven by a more than 4% rise in Apple shares, indicating the positive impact of its strong performance and reinforcing the comeback of the 'Magnificent Seven'.
- Apple's Impressive Earnings: Apple's second-quarter revenue surged 17% to $111.2 billion, surpassing the $109.7 billion estimate, with strong guidance boosting investor confidence and suggesting further stock price increases ahead.
- Eli Lilly's Strong Performance: Eli Lilly's shares rose another 3% following a nearly 10% rally post-earnings, with a remarkable 56% year-over-year revenue increase to $19.8 billion, leading Jim Cramer to assert that selling the stock would be premature.
- Investor Strategy Advice: Jim Cramer advises investors to tune into Apple's earnings call, emphasizing a strategy of holding rather than trading, as he believes there is significant room for the stock to grow, reflecting optimism about its future prospects.
See More
Biotech Dealmaking Accelerates Ahead of Patent Cliffs
- Surge in M&A Activity: Biotech M&A deal value reached $84 billion in Q1 2026, a staggering 89.4% increase from $44.4 billion a year earlier, indicating a robust market recovery, with projections suggesting total annual deal value could exceed $250 billion, ranking second only to 2019.
- Patent Cliffs Catalyst: Pharmaceutical companies are accelerating M&A due to impending patent cliffs, with over $300 billion in revenue facing loss of exclusivity in the next five years, particularly with Merck's Keytruda losing exclusivity in 2028, adding to market uncertainty.
- Strong Cash Reserves Fuel Acquisitions: Eli Lilly, for instance, ended 2025 with over $7.27 billion in cash and equivalents, having spent over $35 billion on acquisitions in 2023, demonstrating that strong financial positions make M&A decisions more justifiable at the board level.
- Mid-Sized Deals Dominate: Recent CEO transitions at GSK and Novo Nordisk have led to more aggressive M&A strategies, with analysts noting that the global revenue exposed to patent expirations over the next seven years is 2.5 times higher than in the last 16 years, further driving the activity in mid-sized deals.
See More
Apple Surpasses Earnings Expectations, Boosts Stock Price
- Apple's Earnings Beat: Apple exceeded analysts' expectations for both earnings and revenue in Q2, resulting in a stock price increase of over 3%, despite iPhone sales falling short, as phone revenue rose 22% from the same period in 2025, indicating strong market demand.
- Supply Chain Challenges: While overall revenue surpassed estimates, CEO Tim Cook warned that the global memory shortage will increasingly impact the business, highlighting the need for the company to remain agile in response to cost pressures.
- Positive Market Reaction: Following the strong earnings report, Apple's stock performed well at market open, reflecting investor confidence in the company's future growth potential, particularly against the backdrop of upcoming product launches.
- Industry Trend Impact: Apple's success also mirrors the recovery of the broader tech sector, with both the Nasdaq Composite and S&P 500 indices reaching all-time highs, showcasing strong demand for tech stocks and investor optimism.
See More
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
Eli Lilly's Foundayo Struggles Against Wegovy in Weight Loss Market
- Market Acceptance Analysis: Eli Lilly's oral GLP-1 drug Foundayo recorded 5,612 prescriptions in its third week, indicating low market acceptance, especially compared to Novo Nordisk's oral Wegovy, which had over 134,000 prescriptions in the same period, highlighting Wegovy's first-mover advantage.
- Patient Treatment Status: As of April 30, Eli Lilly executives reported that over 20,000 patients have been treated with Foundayo; however, this figure appears weak compared to Wegovy's market performance, potentially leading to negative investor sentiment.
- Future Expectations: RBC Capital Markets analyst Trung Huynh expects Foundayo to exceed 90,000 prescriptions by week 12 to stay on track for its annual sales expectation of about $1.4 billion, and achieving this target will directly impact Eli Lilly's market performance and investor confidence.
- Financial Outlook: Eli Lilly projects revenues of $82 billion to $85 billion by 2026, with non-GAAP EPS expected between $35.50 and $37, positioning Foundayo's launch as a crucial component for achieving these targets, despite its current underwhelming market performance.
See More
Apple's Strong Earnings Propel Market to New Highs
- Market Highs: The S&P 500 reached a new intra-day high on Friday, driven by a more than 4% rise in Apple shares, indicating the positive impact of its strong performance and reinforcing the comeback of the 'Magnificent Seven'.
- Apple's Impressive Earnings: Apple's second-quarter revenue surged 17% to $111.2 billion, surpassing the $109.7 billion estimate, with strong guidance boosting investor confidence and suggesting further stock price increases ahead.
- Eli Lilly's Strong Performance: Eli Lilly's shares rose another 3% following a nearly 10% rally post-earnings, with a remarkable 56% year-over-year revenue increase to $19.8 billion, leading Jim Cramer to assert that selling the stock would be premature.
- Investor Strategy Advice: Jim Cramer advises investors to tune into Apple's earnings call, emphasizing a strategy of holding rather than trading, as he believes there is significant room for the stock to grow, reflecting optimism about its future prospects.
See More
Biotech Dealmaking Accelerates Ahead of Patent Cliffs
- Surge in M&A Activity: Biotech M&A deal value reached $84 billion in Q1 2026, a staggering 89.4% increase from $44.4 billion a year earlier, indicating a robust market recovery, with projections suggesting total annual deal value could exceed $250 billion, ranking second only to 2019.
- Patent Cliffs Catalyst: Pharmaceutical companies are accelerating M&A due to impending patent cliffs, with over $300 billion in revenue facing loss of exclusivity in the next five years, particularly with Merck's Keytruda losing exclusivity in 2028, adding to market uncertainty.
- Strong Cash Reserves Fuel Acquisitions: Eli Lilly, for instance, ended 2025 with over $7.27 billion in cash and equivalents, having spent over $35 billion on acquisitions in 2023, demonstrating that strong financial positions make M&A decisions more justifiable at the board level.
- Mid-Sized Deals Dominate: Recent CEO transitions at GSK and Novo Nordisk have led to more aggressive M&A strategies, with analysts noting that the global revenue exposed to patent expirations over the next seven years is 2.5 times higher than in the last 16 years, further driving the activity in mid-sized deals.
See More
Apple Surpasses Earnings Expectations, Boosts Stock Price
- Apple's Earnings Beat: Apple exceeded analysts' expectations for both earnings and revenue in Q2, resulting in a stock price increase of over 3%, despite iPhone sales falling short, as phone revenue rose 22% from the same period in 2025, indicating strong market demand.
- Supply Chain Challenges: While overall revenue surpassed estimates, CEO Tim Cook warned that the global memory shortage will increasingly impact the business, highlighting the need for the company to remain agile in response to cost pressures.
- Positive Market Reaction: Following the strong earnings report, Apple's stock performed well at market open, reflecting investor confidence in the company's future growth potential, particularly against the backdrop of upcoming product launches.
- Industry Trend Impact: Apple's success also mirrors the recovery of the broader tech sector, with both the Nasdaq Composite and S&P 500 indices reaching all-time highs, showcasing strong demand for tech stocks and investor optimism.
See More
